Nonsteroidal anti-inflammatory drugs in ophthalmology

Surv Ophthalmol. 2010 Mar-Apr;55(2):108-33. doi: 10.1016/j.survophthal.2009.07.005.

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are increasingly employed in ophthalmology to reduce miosis and inflammation, manage scleritis, and prevent and treat cystoid macular edema associated with cataract surgery. In addition, they may decrease postoperative pain and photophobia associated with refractive surgery and may reduce the itching associated with allergic conjunctivitis. In recent years, the U.S. Food and Drug Administration has approved new topical NSAIDs, and previously approved NSAIDs have been reformulated. These additions and changes result in different pharmacokinetics and dosing intervals, which may offer therapeutic advantages. For example, therapeutic effects on diabetic retinopathy and age-related macular degeneration may now be achievable. We provide an updated review on NSAIDs and a summary of their current uses in ophthalmology with attention to potential future applications.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage*
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacokinetics
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology
  • Drug Approval
  • Eye Diseases / drug therapy*
  • Eye Diseases / etiology
  • Eye Diseases / metabolism
  • Humans
  • Ophthalmic Solutions / administration & dosage
  • Ophthalmic Solutions / pharmacokinetics
  • Ophthalmic Solutions / pharmacology
  • Ophthalmology / methods*
  • United States
  • United States Food and Drug Administration

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Ophthalmic Solutions